Moderna's Spikevax vaccine is the first to receive full approval for use in children aged 6 months to 11 years with a high-risk health issue.

Enphase Energy (ENPH) retained its spot as the most shorted S&P 500 (SP500) stock as a percentage of float in June, followed ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

Dear J.H.: Metformin, a treatment for diabetes that works mostly by preventing the liver from making sugar, isn't new and has ...

In light of recent revelations surrounding a new intranasal COVID-19 vaccine candidate, there is growing concern that the American public is once again being led into potentially dangerous territory ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added ...

The annual football game at Sportsman's Park in the 1930s drew big crowds ...

The average short interest for the S&P 500 Health Care Index Sector (NYSEARCA:XLV) experienced an increase in June, moving ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

The FDA this week fully approved Moderna’s COVID-19 vaccine for children aged 6 months to 11 years but limited the approval ...

The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one ...